Sialylated IgG Does Not Improve IVIg Efficacy in Mice
Author Information
Author(s): Guhr Theresa, Bloem Judith, Derksen Ninotska I. L., Wuhrer Manfred, Koenderman Anky H. L., Aalberse Rob C., Rispens Theo
Primary Institution: Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
Hypothesis
Does IVIg enriched for sialylated IgG enhance its efficacy in a murine model of immune thrombocytopenia?
Conclusion
Enriching IVIg for sialylated IgG does not enhance its efficacy in treating immune thrombocytopenia in mice.
Supporting Evidence
- IVIg-SA (+) had no effect on platelet count in the murine model.
- IVIg showed a significant increase in platelet count compared to controls.
- SNA lectin fractionation primarily enriched for Fab-sialylated IgG, not Fc-sialylated IgG.
Takeaway
The study found that adding sialic acid to a type of antibody didn't make it work better in mice with low platelet counts.
Methodology
The study used a murine model of passive immune thrombocytopenia to test the efficacy of IVIg and IVIg enriched for sialylated IgG.
Limitations
The study primarily focused on a single animal model and may not be generalizable to other conditions or species.
Participant Demographics
Virgin female Balb/c mice, 6 weeks of age.
Statistical Information
P-Value
p<0.01
Confidence Interval
12.0–14.8
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website